• Sopharma published its Annex 4 consolidated disclosure covering H1 2026, including Q2 2026 developments and unaudited consolidated financial statements.
• Management flagged indirect geopolitical risks from Ukraine and Middle East tensions, citing energy and transport volatility, supply-chain disruption, cost pressure.
• Q2 2026 sales rose in Russia and Ukraine versus the prior-year period.
• Report references disclosures via http://www.x3news.com/ and the Investors section at https://www.sopharmagroup.com/bg/investitori/.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sopharma AD published the original content used to generate this news brief on August 28, 2026, and is solely responsible for the information contained therein.